^
    Back
    Association details:
    Biomarker:NECTIN4 expression
    Cancer:Urothelial Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Springer
    Title:

    Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab

    Published date:
    10/23/2021
    Excerpt:
    PD-L1 expression in tumor cells was associated with poor prognosis (OS and PFS) and low DCR. Interestingly, the strong expression of Nectin-4 was correlated with high DCR. PD-L1 and Nectin-4 expression in tumor cells could be prognostic biomarkers useful for pembrolizumab in patients with advanced UC.